Career Opportunity

Market Access Manager Europe

Life Molecular Imaging is a Research & Development (R&D) organization and a wholly owned subsidiary of Alliance Medical Group Limited. Our vision is to build our position as an innovator and leading player in the Molecular Imaging field. We aim to create value for patients & physicians by improving early detection and characterization of chronic and life-threatening diseases leading to better therapeutic outcomes and improved quality of life.
For our approved PET tracer NeuraCeq® we offer the following full-time position, to be located in Europe:

Market Access Manager Europe *

Key Tasks and Responsibilities:

  • Expand public and private insurance reimbursement for Life Molecular Imaging in Europe and the United Kingdom
  • Develop and implement market access strategies for the above mentioned area
  • Create value propositions to align with local and national health system initiatives
  • Development and maintenance of budget impact and cost effectiveness models, utilize modelling tools to drive technology adoption in public and private settings
  • Relationship development with local and regional reimbursement professionals, procurement, and commissioners.
  • Provide field support in hospitals and clinics to establish funding pathways and drive sustainable access to technologies for patients – leverage local clinical support and key opinion leader networks
  • Work collaboratively with the Country Managers to ensure alignment between national initiatives and local territory needs
  • Drive implementation and uptake of national market access projects at a local territory level
  • Support physician and hospital-level business case development
  • Perform regular horizon scanning to remain up to date on local and national health care initiatives across Europe and the United Kingdom, identify trends and areas of opportunity to expand product reimbursement
  • Participate in congresses and seminars where appropriate

Skills/ Education:

  • Master’s degree in life science, medical and/or specifically in Health Economics
  • Fluency in principles of health economics and their application in the European healthcare environment
  • Able to confidently navigate the European reimbursement and healthcare systems. Familiarity with coding systems i.e. DRG / GOÄ and comparative systems in the other countries
  • Strong project management abilities with a demonstrated record of project development and execution within multidisciplinary teams
  • Several years’ experience within a commercial health care environment
  • Experience with service and/or patient treatment pathway development and implementation in either public or private health care sector
  • Excels in knowledge translation, able to distil complex clinical and economic topics into simple terms
  • Ability to develop clinical and payor networks to support continuity of patient access to care through funding landscape changes
  • Positive Growth Mindset: dynamic, team-centred, motivated to take on new challenges in a fast-paced environment and drive personal and business development
  • Strong interpersonal skills working collaboratively with internal and external stakeholders
  • Fluency in English

If you want to become part of an entrepreneurial team, if you are prepared to assume a wide range of responsibilities and if your background and personal experience fits this profile, please send us your complete application (Cover letter detailing your interest in this position and CV) as a single pdf document to:

Annekathrin Kirchner –
We are looking forward to receiving your application!

* The person counts, not the gender!
Life Molecular Imaging is committed to diversity, rejects discrimination and does not think in categories such as gender, ethnic origin, religion, disability, age or sexual identity.

Life Molecular Imaging GmbH is an Equal Opportunity Employer. We believe what we do and our culture of “More Than a Job. It’s Making Life Better” extends to creating a welcoming, safe, and inclusive work environment.


Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations.

Limitations: Limitations of Use
A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. The safety and effectiveness of Neuraceq have not been established for Predicting the development of dementia or other neurologic conditions or monitoring responses to therapies.



  • Risk for Image Misinterpretation and other Errors
    Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
  • Radiation Risk
    Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.


  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).


  • Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.


  • Pregnancy: All radiopharmaceuticals, including Neuraceq, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering Neuraceq administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation: There are no data on the presence of florbetaben F 18 injection in human milk, the effects on the breastfed infant, or the effects of florbetaben F 18 injection on milk production. Exposure of Neuraceq to a breastfed infant can be minimized by temporary discontinuation of breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Neuraceq and any potential adverse effects on the breastfed child from Neuraceq or from the underlying maternal condition.
  • Pediatric Use: Neuraceq is not indicated for use in pediatric patients.
  • Geriatric Use: No overall differences in safety were observed between older and younger subjects

A pharmacological overdose of Neuraceq is unlikely given the relatively low doses used for diagnostic purposes. In the event of administration of a radiation overdose with Neuraceq, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to Neuraceq administration, please read the full Prescribing Information for additional Important Safety Information.